Cosmo Pharmaceuticals N.V.
Symbol: COPN.SW
SIX
71.4
CHFMarktpreis heute
1009.1513
P/E-Verhältnis
14.6994
PEG-Verhältnis
1.15B
MRK Kapital
- 0.01%
DIV Rendite
Cosmo Pharmaceuticals N.V. (COPN-SW) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 50.3 | 241 | 222.2 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 55.1 | 23.6 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 28.5 | 38.6 | 24.5 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 14.2 | 11.5 | 13.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 9.3 | 53.6 | 39.7 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 102.2 | 306.1 | 275.8 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 28.6 | 30.3 | 30.5 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 24 | 24 | 24 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 355.6 | 366.8 | 372.7 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 379.6 | 390.8 | 396.7 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 3.3 | -46.9 | 25.4 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 14.7 | 18.6 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 40.3 | 64.5 | 58.4 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 451.8 | 453.5 | 529.7 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 8.8 | 10.7 | 11.6 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 171.8 | 0.9 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 2.7 | 3.6 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.9 | 1.8 | 169 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.5 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 14.3 | 12.5 | 3.2 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 97.2 | 100.9 | 271.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 2 | 2.6 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 120.3 | 295.8 | 292.9 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 11.5 | 18.4 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 4.6 | 4.6 | 4.6 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 302.6 | 262.2 | 293.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -22.7 | -11.5 | -18.4 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 142.3 | 190.1 | 207.4 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 426.8 | 456.9 | 505.3 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 554 | 759.6 | 805.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 6.9 | 6.9 | 7.4 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | 433.6 | 463.8 | 512.7 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 3.3 | 8.3 | 49.1 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 1.1 | 173.6 | 169.9 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | -49.2 | -12.2 | -28.6 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 24.5 | 24 | -6.9 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.9 | 7.4 | 6 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -21.4 | 5.9 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 2.1 | 1.5 | 9 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -13.3 | -5.1 | -5.1 | |||||||||||||||||||
cash-flows.row.account-receivables | 0 | -14.2 | 3.3 | -7.9 | |||||||||||||||||||
cash-flows.row.inventory | 0 | 1.6 | -6.1 | 0.4 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | 14.2 | -3.3 | 7.9 | |||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -14.9 | 1 | -5.6 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 6.1 | 6.2 | 4.2 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 23.3 | -4.1 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -54 | -1 | -20 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 35.9 | 7.7 | 131.6 | |||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 27.1 | 3.3 | -23.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 1.7 | 24.9 | 75.4 | |||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -0.9 | -2.6 | -1.8 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.3 | 0.8 | 5.3 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -24.7 | -19.7 | -11 | |||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -15.6 | -0.8 | 0 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -5.1 | -4.9 | -4.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -46.1 | -27.2 | -11.9 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.5 | 2.4 | -1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -12.7 | 12.6 | 75.5 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 185.8 | 198.6 | 185.9 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 198.6 | 185.9 | 110.4 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 33.2 | 12.6 | 13 | |||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -7.3 | -8.5 | -8.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 25.9 | 4.1 | 4.9 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 96.7 | 102.1 | 65.1 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 39.3 | 18.8 | 15.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 57.4 | 83.3 | 49.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 45.3 | 55.3 | 38.8 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 84.7 | 74 | 54 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 4.5 | 2.9 | 3.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 51.7 | 36 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -4.6 | -3.6 | -9.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 9.2 | 9 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 13.6 | 19.4 | 7.4 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | 12.2 | 28.1 | 33.1 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 7.6 | 24.5 | 24 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 6.3 | 7 | 2.3 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | 1.1 | 17.2 | 21.7 |
Häufig gestellte Frage
Wie hoch ist die Cosmo Pharmaceuticals N.V. (COPN.SW) Gesamtvermögen?
Cosmo Pharmaceuticals N.V. (COPN.SW) Gesamtvermögen ist 553980000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.593.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 1.901.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.012.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.126.
Was ist der Cosmo Pharmaceuticals N.V. (COPN.SW) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 1147000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1079000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 45314000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.